作者
Willem Evert Van Spil, Olga Kubassova, Mikael Boesen, Anne-Christine Bay-Jensen, Ali Mobasheri
发表日期
2019/7/1
来源
Biochemical pharmacology
卷号
165
页码范围
41-48
出版商
Elsevier
简介
The success of disease-modifying osteoarthritis drug (DMOAD) development is still elusive. While there have been successes in preclinical and early clinical studies, phase 3 clinical trials have failed so far and there is still no approved, widely available DMOAD on the market. The latest research suggests that, among other causes, poor trial outcomes might be explained by the fact that osteoarthritis (OA) is a heterogeneous disease with distinct phenotypes. OA trials might be more successful if they would address and target a specific phenotype.
The increasing availability of advanced techniques to detect particular OA characteristics expands the possibilities to distinguish between such potential OA phenotypes. Magnetic resonance imaging is among the key imaging techniques to stratify and monitor patients with changes in bone, cartilage and inflammation. Biochemical markers have mainly used as secondary …
引用总数
20192020202120222023202493350413712
学术搜索中的文章
WE Van Spil, O Kubassova, M Boesen, AC Bay-Jensen… - Biochemical pharmacology, 2019